Alanyl-glutamine

Phase 3Small molecule

UUniversity of Virginia

Alanyl-glutamine is one of 31 small molecule programs targeting Malnutrition. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalnutritionActive, not recruiting

MalnutritionPhase 3

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Malnutrition

#DrugCompanyPhaseTrials

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

9 2

Thalomid

Bristol-Myers Squibb

Approved

1 3

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 4

Lialda

Takeda

Approved

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Garamycin

2 7

Penbritin-S

Bristol-Myers Squibb

Phase 3

1 8

Flagyl

DDePuy Orthopaedics

Phase 3

1 9

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

1 10

Typhoid Conjugate Vaccine

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Treatment

NCT04305769

Clinical

Trials by Indication[1]

Treatment2 trials

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

Terminated·UUniversity of Virginia·Phase 2·NCT02053350·7 enrolled

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

Recruiting·UUniversity of Virginia·Phase 2·NCT04305769·260 enrolled

Malnutrition2 trials

Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition

Withdrawn·UUniversity of Virginia·Phase 3·NCT00338221·108 enrolled

HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition

Withdrawn·UUniversity of Virginia·Phase 3·NCT00133562·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Alanyl-glutamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alanyl-glutamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alanyl-glutamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Virginia

Alanyl-glutamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Treatment2 trials

Malnutrition2 trials

References

Drug Info

Quick Facts

Related News